Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
IMV Inc
IMVIF
Healthcare
Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:IMVIF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(1)
•••
Jthom376
X
View Profile
View Bullboard History
Post by
Jthom376
on Apr 10, 2022 6:18pm
PRESENTATION
https://d1io3yog0oux5.cloudfront.net/_bfcd68f81a7671ab219059215c036403/imvinc/db/937/8666/pdf/Slide_Deck_for_website.pdf
(5)
•••
Biotech010
X
View Profile
View Bullboard History
Comment by
Biotech010
on Apr 09, 2022 2:50pm
RE:To me
coming week is the Wells Fargo biotech conference, chances are the BUY from WF will be reiterated
(2)
•••
europe10
X
View Profile
View Bullboard History
Post by
europe10
on Apr 09, 2022 2:43pm
To me
I will let the brokers come out with comments, but to me they are encouraging. It has been a ling journey but things appear to be coming together. Step by step. IMV might get there. On the other
...more
(5)
•••
Biotech010
X
View Profile
View Bullboard History
Comment by
Biotech010
on Apr 09, 2022 6:41am
RE:RE:RE:RE:RE:Presentations
I like the fact that patients who lacked benefit from Pembro, are getting better when MVP is added to the mix. Looking forward to the presentation and the stock on monday!
(2)
•••
Breakthorough
X
View Profile
View Bullboard History
Comment by
Breakthorough
on Apr 08, 2022 2:06pm
RE:RE:RE:RE:Presentations
ORR: 29'4% (CR 11'8%, PR: 17'6%) mOS (Overall Survival): not reached. But "long-term clinical benefit has been observed in several subjects (one patient is still on treatment after 17
...more
(0)
•••
LR6852
X
View Profile
View Bullboard History
Comment by
LR6852
on Apr 08, 2022 1:16pm
RE:RE:RE:Presentations
Abstract is now available online: Background: Maveropepimut-S (MVP-S) is a novel immunotherapeutic that educates a specific CD8 T cell response to the cancer antigen, survivin, to orchestrate
...more
(0)
•••
LR6852
X
View Profile
View Bullboard History
Comment by
LR6852
on Apr 05, 2022 4:28pm
RE:RE:Presentations
Here it is: https://www.abstractsonline.com/pp8/#!/10517/presentation/20386
(6)
•••
Hideaway
X
View Profile
View Bullboard History
Comment by
Hideaway
on Apr 05, 2022 1:16pm
RE:Presentations
On reflection,it seems odd that there is no mention of the AACR oral presentation slated for April 12th. Does anyone have any info to confirm their AACR attendance? After reading the last NR,they
...more
(6)
•••
Hideaway
X
View Profile
View Bullboard History
Post by
Hideaway
on Apr 04, 2022 9:41am
Presentations
IMV will be giving AACR presentation on Apr.12th plus the following two around the same time.Hope they prove to be more productive than past presentations. APRIL 04, 2022 7:05AM EDT
...more
(5)
•••
Biotech010
X
View Profile
View Bullboard History
Comment by
Biotech010
on Mar 24, 2022 12:44pm
RE:RE:AARC Presentation,DPX Platform Recognition,or Partnership?
CFO Pierre sais on a webcast in 2021 that a license deal was possible in Q1 2022. Now that Q1 is almost over...a deal should be coming soon. The CEO is now pushing on with the DPX platform.... so we
...more
(17)
•••
alphaseeking001
X
View Profile
View Bullboard History
Comment by
alphaseeking001
on Mar 22, 2022 3:37pm
RE:AARC Presentation,DPX Platform Recognition,or Partnership?
No additional info Hideaway. I spoke with IR about 6 weeks ago because I was frustrated and he seemed pretty upbeat but I've learned not to read much into that. The late breaking
...more
(6)
•••
Hideaway
X
View Profile
View Bullboard History
Post by
Hideaway
on Mar 22, 2022 10:41am
AARC Presentation,DPX Platform Recognition,or Partnership?
IMV seems to finally be getting some recognition amongst investors.All the above are possible drivers but just speculation at the moment.The AARC presentation on April 12th could provide some
...more
(5)
•••
Biotech010
X
View Profile
View Bullboard History
Comment by
Biotech010
on Mar 20, 2022 5:09pm
RE:RE:Capitalize on DPX platform in 2022
take a few minutes to read this: https://seekingalpha.com/article/4496254-imv-inc-imv-ceo-andrew-hall-on-q4-2021-results-earnings-call-transcript
(5)
•••
Biotech010
X
View Profile
View Bullboard History
Comment by
Biotech010
on Mar 20, 2022 5:02pm
RE:Capitalize on DPX platform in 2022
Very strong close last friday on good volume. Thew technical picture looks bright. But more important, we finally have management that can sell the platform. They mentioned using other platform deals
...more
(4)
•••
antigua1987
X
View Profile
View Bullboard History
Post by
antigua1987
on Mar 18, 2022 9:56am
Let's hope imv's name does not come up
CTV: 'WHO pauses approval of Quebec's Medicago COVID-19 vaccine due to tobacco industry ties' Hello imv risk managament? did anyone look into this connection and evaluate downside? Board
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >